Fasedienol (original) (raw)
Fasedienol (INN; developmental code names PH94B and Aloradine), also known as 4-androstadienol or as 4,16-androstadien-3β-ol, is a pherine which is under development by VistaGen Therapeutics in a nasal spray formulation (PRN) for the acute treatment of social anxiety disorder. It is also being investigated by VistaGen Therapeutics for the treatment of generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). The pherine is a positional isomer of the endogenous pheromone androstadienol (5-androstadienol or 5,16-androstadien-3β-ol). As of 2020, it is in phase III clinical trials for social anxiety disorder.
| Property | Value |
|---|---|
| dbo:abstract | Fasedienol (INN; developmental code names PH94B and Aloradine), also known as 4-androstadienol or as 4,16-androstadien-3β-ol, is a pherine which is under development by VistaGen Therapeutics in a nasal spray formulation (PRN) for the acute treatment of social anxiety disorder. It is also being investigated by VistaGen Therapeutics for the treatment of generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). The pherine is a positional isomer of the endogenous pheromone androstadienol (5-androstadienol or 5,16-androstadien-3β-ol). As of 2020, it is in phase III clinical trials for social anxiety disorder. Fasedienol lacks affinity for steroid hormone receptors and has instead been found to directly activate isolated human vomeronasal receptor cells at nanomolar concentrations (EC50 = 200 nM). The pheromone androstenol has been found to act as a potent positive allosteric modulator of the GABAA receptor, and it has been proposed that this action may mediate its pheromone effects. It produces anxiolytic-like effects in animals. Androstadienol, androstadienone, and androstenone, all of which are also pheromones, have been found to be converted into androstenol, and as such, it may be responsible for their pheromone effects. As fasedienol is very closely related structurally to androstadienol, it might be converted into androstenol similarly and hence potentiation of the GABAA receptor could contribute to its mechanism of action. (en) |
| dbo:casNumber | 23062-06-8 |
| dbo:drugbank | DB04968 |
| dbo:fdaUniiCode | DTW1NJ7IJH |
| dbo:pubchem | 9925482 |
| dbo:thumbnail | wiki-commons:Special:FilePath/4,16-Androstadien-3β-ol.svg?width=300 |
| dbo:wikiPageExternalLink | https://www.vistagen.com/pipeline/PH94B/overview http://adisinsight.springer.com/drugs/800014893 |
| dbo:wikiPageID | 46784921 (xsd:integer) |
| dbo:wikiPageLength | 8596 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1107688868 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Androstadienol dbr:EC50 dbr:List_of_investigational_anxiolytics dbr:List_of_neurosteroids dbr:Intranasal dbc:Androstanes dbc:Pherines dbr:Generalized_anxiety_disorder dbr:Phase_III_clinical_trials dbr:Androstadienone dbr:Androstenol dbr:Androstenone dbr:Anxiolytic dbr:Clinical_trial dbr:Positive_allosteric_modulator dbr:Pro_re_nata dbr:Nasal_spray dbr:Cell_(biology) dbr:GABAA_receptor dbr:Vomeronasal_receptor dbc:Anxiolytics dbr:Endogenous dbr:Affinity_(pharmacology) dbr:Pherine dbr:Posttraumatic_stress_disorder dbr:Nanomolar dbr:Social_anxiety_disorder dbr:Steroid_hormone_receptor dbr:Positional_isomer |
| dbp:atcPrefix | None (en) |
| dbp:c | 19 (xsd:integer) |
| dbp:casNumber | 23062 (xsd:integer) |
| dbp:chemspiderid | 8101117 (xsd:integer) |
| dbp:drugbank | DB04968 (en) |
| dbp:h | 28 (xsd:integer) |
| dbp:iupacName | -1013 (xsd:integer) |
| dbp:o | 1 (xsd:integer) |
| dbp:pubchem | 9925482 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Intranasal |
| dbp:smiles | C[C@]12CC[C@H]3[C@H]CCC4=C[C@H]O (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | NYVFCEPOUVGTNP-DYKIIFRCSA-N (en) |
| dbp:synonyms | PH94B; Aloradine; 4-Androstadienol; 3β-Androsta-4,16-dien-3-ol, Androsta-4,16-dien-3β-ol; Androstadienol (en) |
| dbp:unii | DTW1NJ7IJH (en) |
| dbp:width | 225 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Pheromones_and_pherines dbt:Drugbox dbt:Nbsp dbt:Reflist dbt:Abbrlink dbt:Fdacite dbt:Anxiolytics |
| dcterms:subject | dbc:Androstanes dbc:Pherines dbc:Anxiolytics |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Fasedienol (INN; developmental code names PH94B and Aloradine), also known as 4-androstadienol or as 4,16-androstadien-3β-ol, is a pherine which is under development by VistaGen Therapeutics in a nasal spray formulation (PRN) for the acute treatment of social anxiety disorder. It is also being investigated by VistaGen Therapeutics for the treatment of generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). The pherine is a positional isomer of the endogenous pheromone androstadienol (5-androstadienol or 5,16-androstadien-3β-ol). As of 2020, it is in phase III clinical trials for social anxiety disorder. (en) |
| rdfs:label | Fasedienol (en) |
| owl:sameAs | wikidata:Fasedienol https://global.dbpedia.org/id/xnTK |
| prov:wasDerivedFrom | wikipedia-en:Fasedienol?oldid=1107688868&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/4,16-Androstadien-3β-ol.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Fasedienol |
| is dbo:wikiPageRedirects of | dbr:4,16-Androstadien-3β-ol dbr:Androsta-4,16-dien-3β-ol dbr:4-Androstadienol dbr:PH-94B dbr:PH94B dbr:PH_94B dbr:Aloradine dbr:Aloradine_IN dbr:3β-Androsta-4,16-dien-3-ol dbr:3β-androsta-4,16-dien-3-ol dbr:4,16-androstadien-3β-ol dbr:4-androstadienol dbr:(3β)-Androsta-4,16-dien-3-ol dbr:(3β)-androsta-4,16-dien-3-ol |
| is dbo:wikiPageWikiLink of | dbr:4,16-Androstadien-3β-ol dbr:Androsta-4,16-dien-3β-ol dbr:List_of_investigational_anxiolytics dbr:List_of_neurosteroids dbr:4-Androstadienol dbr:Pherine dbr:PH-94B dbr:PH94B dbr:PH_94B dbr:Aloradine dbr:Aloradine_IN dbr:3β-Androsta-4,16-dien-3-ol dbr:3β-androsta-4,16-dien-3-ol dbr:4,16-androstadien-3β-ol dbr:4-androstadienol dbr:(3β)-Androsta-4,16-dien-3-ol dbr:(3β)-androsta-4,16-dien-3-ol |
| is foaf:primaryTopic of | wikipedia-en:Fasedienol |
